KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 9, 2007, Pages 635-642

  An, She Juan ^a   Nie, Qiang ^a   Chen, Zhi Hong ^a   Lin, Qiu Xiong ^a   Wang, Zhen ^a   Xie, Zhi ^a   Chen, Shi Liang ^a   Huang, Ying ^a   Zhang, Ai Ye ^a   Yan, Jin Feng ^a   Wu, Hong Sui ^a   Lin, Jia Ying ^a   Li, Rong ^a   Zhang, Xu Chao ^a   Guo, Ai Lin ^a   Mok, Tony S ^b   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Clinical parameter; Gene expression; Kinase insert domain containing receptor; Lung cancer

Indexed keywords

VASCULOTROPIN RECEPTOR 2;

ANALYSIS OF VARIANCE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LINEAR REGRESSION ANALYSIS; LOG RANK TEST; LUNG CANCER; LUNG CARCINOMA; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STUDENT T TEST;

ADULT; AGED; AGED, 80 AND OVER; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMOKING; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 34447527084     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0214-0     Document Type: Article

References (38)

1. Baffert F, Thurston G, Rochon-Duck M, Le T, Brekken R, McDonald DM (2004) Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res 4:984-992
2. Bremnesa RM, Sirerab R, Camps C (2005) Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 49:1-12
3. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932-936
4. Coultas L, Chawengsaksophak K, Rossant J (2005) Endothelial cells and VEGF in vascular development. Nature 438:937-945
5. Dayanir V, Meyer RD, Lashkari K, Rahimi N (2001) Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J Biol Chem 276:17686-17692
6. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338-340
7. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974
8. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594-2601
9. Goll R, Olsen T, Cui G, Florholmen J (2006) Evaluation of absolute quantitation by nonlinear regression in probe-based real-time PCR. BMC Bioinformatics 7:107
10. He JW, Jiang S (2005) Quantification of enterococci and human adenoviruses in environmental samples by real-time PCR. Appl Environ Microbiol 71:2250-2255
11. Herbst RS, Sandler AB (2004) Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 9:19-26
12. Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23:3243-3256
13. Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G, Woll E, Kahler CM (2004) CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 57:965-969
14. Hubbard SR (1999) Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol 71:343-358
15. Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, Georgoulias V, Gatter KC, Harris AL (2000) Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60:3088-3095
16. Le Boeuf F, Houle F, Huot J (2004) Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem 279:39175-39185
17. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
18. Massarelli E, Herbst RS (2006) Use of novel second-line targeted therapies in non-small cell lung cancer. Semin Oncol 33: 9-16
19. McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5:3-10
20. Meyer RD, Dayanir V, Majnoun F, Rahimi N (2002) The presence of a single tyrosine residue at the carboxyl domain of vascular endothelial growth factor receptor-2/FLK-1 regulates its autophosphorylation and activation of signaling molecules. J Biol Chem 277:27081-27087
21. Meyer RD, Latz C, Rahimi N (2003) Recruitment and activation of phospholipase Cgamma1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells. J Biol Chem 278:16347-16355
22. Maione P, Gridelli C, Troiani T, Ciardiello F (2006) Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist 11:274-284
23. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846
24. Nakamura K, Yamamoto A, Kamishohara M, Takahashi K, Taguchi E, Miura T, Kubo K, Shibuya M, Isoe T (2004) KRN633: a selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol Cancer Ther 3:1639-1649
25. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
26. Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437-443
27. Robinson CJ, Stringer SE (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114:853-865
28. Rosell R, Felip E, Garcia-Campelo R, Balana C (2004) The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer 46:135-148
29. Sebolt-Leopold JS, English JM (2006) Mechanisms of drug inhibition of signaling molecules. Nature 441:457-462
30. Singh AJ, Meyer RD, Band H, Rahimi N (2005) The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation. Mol Biol Cell 16:2106-2118
31. Stewart M, Turley H, Cook N, Pezzella F, Pillai G, Ogilvie D, Cartlidge S, Paterson D, Copley C, Kendrew J, Barnes C, Harris AL, Gatter KC (2003) The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study. Histopathology 43:33-39
32. Strawn LM, Shawver LK (1998) Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Expert Opin Investig Drugs 7:553-573
33. Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K (2004) Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Sci 95:984-989
34. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655
35. Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC, Yang PC (2005) Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 115:545-555
36. Zakarija A, Soff G (2005) Update on angiogenesis inhibitors. Curr Opin Oncol 17:578-583
37. Zeng H, Sanyal S, Mukhopadhyay D (2001) Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 276:32714-32719
38. Zhang G, Zhao M, Xu M, Yang Y, Wang M, Yang C (2002) Correlation of angiogenesis with expression of vascular endothelial growth factor and its receptors in lung carcinoma. Chin J Tuberc Respir Dis 25:89-93